Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy

To address the COVID-19 pandemic, there has been an unprecedented global effort to advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical efforts to advance antiviral monoclonal antibodies (mAbs) for the treatment of other respiratory infections have been met with c...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz-Teran, Carlos, Tiruthani, Karthik, McSweeney, Morgan, Ma, Alice, Pickles, Raymond, Lai, Samuel K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833882/
https://www.ncbi.nlm.nih.gov/pubmed/33309815
http://dx.doi.org/10.1016/j.addr.2020.12.004
_version_ 1783642161284120576
author Cruz-Teran, Carlos
Tiruthani, Karthik
McSweeney, Morgan
Ma, Alice
Pickles, Raymond
Lai, Samuel K.
author_facet Cruz-Teran, Carlos
Tiruthani, Karthik
McSweeney, Morgan
Ma, Alice
Pickles, Raymond
Lai, Samuel K.
author_sort Cruz-Teran, Carlos
collection PubMed
description To address the COVID-19 pandemic, there has been an unprecedented global effort to advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical efforts to advance antiviral monoclonal antibodies (mAbs) for the treatment of other respiratory infections have been met with categorical failures in the clinic. By investigating the mechanism by which SARS-CoV-2 and similar viruses spread within the lung, along with available biodistribution data for systemically injected mAb, we highlight the challenges faced by current antiviral mAbs for COVID-19. We summarize some of the leading mAbs currently in development, and present the evidence supporting inhaled delivery of antiviral mAb as an early intervention against COVID-19 that could prevent important pulmonary morbidities associated with the infection.
format Online
Article
Text
id pubmed-7833882
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-78338822021-01-26 Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy Cruz-Teran, Carlos Tiruthani, Karthik McSweeney, Morgan Ma, Alice Pickles, Raymond Lai, Samuel K. Adv Drug Deliv Rev Article To address the COVID-19 pandemic, there has been an unprecedented global effort to advance potent neutralizing mAbs against SARS-CoV-2 as therapeutics. However, historical efforts to advance antiviral monoclonal antibodies (mAbs) for the treatment of other respiratory infections have been met with categorical failures in the clinic. By investigating the mechanism by which SARS-CoV-2 and similar viruses spread within the lung, along with available biodistribution data for systemically injected mAb, we highlight the challenges faced by current antiviral mAbs for COVID-19. We summarize some of the leading mAbs currently in development, and present the evidence supporting inhaled delivery of antiviral mAb as an early intervention against COVID-19 that could prevent important pulmonary morbidities associated with the infection. Elsevier B.V. 2021-02 2020-12-09 /pmc/articles/PMC7833882/ /pubmed/33309815 http://dx.doi.org/10.1016/j.addr.2020.12.004 Text en © 2020 Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Cruz-Teran, Carlos
Tiruthani, Karthik
McSweeney, Morgan
Ma, Alice
Pickles, Raymond
Lai, Samuel K.
Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
title Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
title_full Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
title_fullStr Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
title_full_unstemmed Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
title_short Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
title_sort challenges and opportunities for antiviral monoclonal antibodies as covid-19 therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7833882/
https://www.ncbi.nlm.nih.gov/pubmed/33309815
http://dx.doi.org/10.1016/j.addr.2020.12.004
work_keys_str_mv AT cruzterancarlos challengesandopportunitiesforantiviralmonoclonalantibodiesascovid19therapy
AT tiruthanikarthik challengesandopportunitiesforantiviralmonoclonalantibodiesascovid19therapy
AT mcsweeneymorgan challengesandopportunitiesforantiviralmonoclonalantibodiesascovid19therapy
AT maalice challengesandopportunitiesforantiviralmonoclonalantibodiesascovid19therapy
AT picklesraymond challengesandopportunitiesforantiviralmonoclonalantibodiesascovid19therapy
AT laisamuelk challengesandopportunitiesforantiviralmonoclonalantibodiesascovid19therapy

Ejemplares similares